Listar por autor "Escors Murugarren, David"
Mostrando ítems 21-24 de 24
-
Study of two barriers in melanoma immunotherapy; myeloid derived suppressor cells and PD-L1/P-D1 inhibitory interaction
Los tumores escapan eficazmente del ataque inmunitario al inhibir las actividades antitumorales de las células T. Esto se logra mediante al menos dos mecanismos principales. En primer lugar por el establecimiento de ... -
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
Escors Murugarren, David; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Blanco, Ester; Piñeiro Hermida, Sergio; Garnica, Maider; Fernández Rubio, Leticia; Vera García, Ruth; Arasanz Esteban, Hugo; Kochan, Grazyna (MDPI, 2022) Artículo / ArtikuluaPD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic ... -
TNF-α-secreting tumor-infiltrated monocytes play a pivotal role during anti-PD-L1 immunotherapy
Zuazo Ibarra, Miren ; Ridder, Kirsten de; Locy, Hanne; Piccioni, Elisa; Awad, Robin Maximilian; Verhulst, Stefaan; Van Bulck, Mathias; Vlaeminck, Yannick de; Lecoq, Quentin; Reijimen, Eva; Mey, Wout de; Beck, Lien de; Ertveldt, Thomas; Pintelon, Isabel; Timmermans, Jean-Pierre; Escors Murugarren, David; Keyaerts, Marleen; Breckpot, Karine; Goyvaerts, Cleo (Frontiers Media, 2022) Artículo / ArtikuluaImmune checkpoint blockade (ICB) of the PD-1 pathway revolutionized the survival forecast for advanced non-small cell lung cancer (NSCLC). Yet, the majority of PD-L1+ NSCLC patients are refractory to anti-PD-L1 therapy. ... -
Understanding LAG-3 Signaling
Chocarro, Luisa ; Blanco, Ester; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Fernández Rubio, Leticia; Morente Sancho, Pilar; Fernández Hinojal, Gonzalo; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2021) Artículo / ArtikuluaLymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...